Ko, H., Previs, R. A., Strickland, K. C., Klein, J., Caveney, B., Chiruzzi, C., … Saini, K. S. (2024). Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate? Oncol Ther, 12(1), 13–17. https://doi.org/10.1007/s40487-023-00249-0

Ko, Heidi, Rebecca A. Previs, Kyle C. Strickland, Jonathan Klein, Brian Caveney, Chiara Chiruzzi, Marcia Eisenberg, Eric A. Severson, Shakti Ramkissoon, and Kamal S. Saini. “Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?” Oncol Ther 12, no. 1 (March 2024): 13–17. https://doi.org/10.1007/s40487-023-00249-0.

Ko H, Previs RA, Strickland KC, Klein J, Caveney B, Chiruzzi C, et al. Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate? Oncol Ther. 2024 Mar;12(1):13–7.

Ko, Heidi, et al. “Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?” Oncol Ther, vol. 12, no. 1, Mar. 2024, pp. 13–17. Pubmed, doi:10.1007/s40487-023-00249-0.

Ko H, Previs RA, Strickland KC, Klein J, Caveney B, Chiruzzi C, Eisenberg M, Severson EA, Ramkissoon S, Saini KS. Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate? Oncol Ther. 2024 Mar;12(1):13–17.